For example, some AML patients may benefit from antagonism of all RARs because leukemogenesis was delayed and stemness was reduced in an Evi1high and MA-9 driven mouse model of AML by the pan-RAR antagonist AGN193109 [61]. The gene discussed is RARS1; the disease is acute myeloid leukemia.